Your browser doesn't support javascript.
loading
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim, Sang Kyum; Kim, Jee Hung; Kim, Seung Hyun; Lee, Young Han; Han, Jung Woo; Baek, Wooyeol; Woo, Ha Young; Jeon, Min Kyung; Kim, Hyo Song.
Afiliação
  • Kim SK; Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim JH; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim SH; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee YH; Department of Radiology, Yonsei University College of Medicine, Seoul, South Korea.
  • Han JW; Division of Pediatric Hemato-Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.
  • Baek W; Department of Plastic Surgery, Yonsei University College of Medicine, Seoul, South Korea.
  • Woo HY; Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
  • Jeon MK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. hyosong77@yuhs.ac.
BMC Cancer ; 21(1): 336, 2021 Mar 31.
Article em En | MEDLINE | ID: mdl-33789622
BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predictive impact of PD-L1, we investigated the clinical relevance of PD-L1 expression and evaluated its value for predicting pazopanib efficacy. METHODS: Tumour tissues from patients with advanced STS who went on to receive pazopanib were assessed for PD-L1 expression. Immunohistochemistry was performed using an anti-PD-L1 antibody, and the PD-L1 tumour proportion score (TPS) was calculated as the percentage of at least 100 viable cells with positive expression, defined as TPS ≥ 1%. RESULTS: Among the 67 patients, 8 (11.9%) achieved partial response and a median progression-free survival (PFS) of 4.8 months (95% CI 3.8-5.7). PD-L1 expression in tumour cells was detected in 13 (19.4%) cases and the TPS scores ranged from 1 to 100%, as follows: 0 (n = 54, 80.6%), 1-9% (n = 3, 4.5%), 10-49% (n = 9, 13.4%), and ≥ 50% (n = 1, 1.5%). PD-L1 positive tumours exhibited a poorer response to pazopanib treatment than the PD-L1 negative tumours (0% vs 14.8%, P = 0.07). PD-L1-positive tumours had significantly shorter PFS than the PD-L1-negative tumours (median PFS 2.8 vs 5.1 months, P = 0.003), and PD-L1 positivity was an independent predictor of poor response to pazopanib treatment (HR 2.77, 95% CI; 1.45-5.56, P = 0.006). CONCLUSION: We identified that PD-L1 expression can help predict the clinical outcome of patients with advanced STS treated with pazopanib. Based on our study, stratification should be actively considered in order to identify patients who will benefit from pazopanib or further therapeutic strategies for future clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sarcoma / Sulfonamidas / Inibidores da Angiogênese / Antígeno B7-H1 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sarcoma / Sulfonamidas / Inibidores da Angiogênese / Antígeno B7-H1 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul